89 results about "Inhalation preparations" patented technology

The present invention relates to (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in the form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (IMI) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2- The present invention relates to a pharmaceutical dry powder formulation comprising {[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) in combination with a lactose carrier comprising lactose monohydrate as a mixture of coarse and fine lactose, a process for producing such a pharmaceutical dry powder formulation, and its application for use in the treatment of cardiopulmonary disorders such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary hypertension (PH) associated with chronic lung diseases (group 3 PH), such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP).

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a beclomethasone propionate suspension for inhalation and a preparation method thereof. The beclomethasone propionate suspension for inhalation comprises beclomethasone propionate, a suspending stabilizer and a propellant, and the preparation method comprises the steps of raw material crushing, suspending stabilizer pretreatment, dynamic circulating temperature control mixing, high-pressure homogenization and the like. The settling volume ratio of the suspension is obviously superior to that in the prior art. The preparation provided by the invention has excellent physical and chemical stability and loose storage conditions, and provides a safe and efficient inhalation preparation choice for the treatment of respiratory diseases.

The invention relates to the technical field of pharmaceutical preparations, in particular to inhalable drug-loaded nanoparticles as well as a preparation method and application thereof. The drug-loaded nanoparticles comprise a polymer nano-carrier and nintedanib loaded on the polymer nano-carrier through a hydrogen bond, the polymer nano-carrier is obtained by self-assembling cationic polysaccharide and an anionic polymer through electrostatic interaction. The cationic polysaccharide and the anionic polymer form a polymer nano-carrier with a stable internal structure through electrostatic interaction, and the entrapment efficiency of the nintedanib can be remarkably improved. The drug-loaded nanoparticles prepared by adopting an ionic cross-linking method are uniform in particle size, have good bioavailability and slow-release treatment effect, and can be used as a powerful choice for treating idiopathic pulmonary fibrosis as a lung inhalation preparation.

This invention provides a novel nebulization suspension comprising amoxicillin and clavulanate for the effective treatment of pneumonia. The formulation is specifically designed for pulmonary delivery, offering several advantages over traditional oral antibiotics. Key features include mucoadhesive properties that enhance drug retention 5 in the lungs, sustained release characteristics for prolonged therapeutic action, and potential biofilm disruption to combat antibiotic resistance. This localized delivery approach aims to minimize systemic side effects, improve treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia.

The present invention relates to nanocarrier formulations for the treatment of bacterial infections of the lower airway by inhalation therapy.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

The invention discloses aztreonam microspheres as well as a preparation method and application thereof. The microsphere is an inhalation preparation and can be effectively deposited in the lung, so that the slow release of the medicine is realized. According to the aztreonam microspheres, aztreonam and cinnamyl aldehyde are synthesized into a small molecule drug, and the small molecule drug is self-assembled into the microspheres. The preparation method comprises the following steps: (1) placing aztreonam AZT and cinnamyl aldehyde CA in a glass bottle according to a molar ratio of 3: 2, adding dimethyl sulfoxide DMSO, stirring and dissolving, and stirring and reacting at room temperature for 5-7 hours; (2) dialyzing the reacted solution in a dialysis bag, removing DMSO and unreacted small molecules, and obtaining dialysate after 48 hours; (3) performing freeze drying to obtain yellow powder of cinnamyl aldehyde-aztreonam CAT; and (4) weighing the CAT powder, dissolving the CAT powder in deionized water, and shaking to dissolve the CAT powder to obtain the aztreonam microspheres. The microspheres are suitable for treatment of pulmonary infections, in particular for local drug delivery and sustained release control.

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.

The invention discloses a humidity guaranteeing device for a laser particle analyzer applied to inhalation preparation detection, and belongs to the technical field of medical instruments, the humidity guaranteeing device comprises a wet gas generating device and a gas pipeline, the wet gas generating device comprises a gas inlet and a gas outlet, and the gas outlet is in sealed connection with the gas pipeline; a sample bin and a fog drop testing device are mounted on the gas pipeline, and the sample bin is positioned between the fog drop testing device and the gas outlet; the sample bin is provided with a medicine containing cavity, the medicine containing cavity is communicated with the gas pipeline, the fog drop testing device is provided with a fog drop containing cavity, the fog drop containing cavity is communicated with the sample bin, and the fog drop testing device is provided with a first light-transmitting part and a second light-transmitting part. The device can be adapted to a laser particle analyzer, fog drops can meet requirements when the laser particle analyzer is used for detection, and an accurate detection result is obtained.

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

The present invention relates to the field of pharmaceutical preparations, and particularly to an ambroxol hydrochloride solution, a preparation method thereof and an application thereof. In the present invention, diethylenetriaminepentaacetic acid is used as a stabilizer component of the ambroxol hydrochloride solution in a relatively small amount. Diethylenetriaminepentaacetic acid has strong coordination ability and can interact with other molecules in the solution, thereby greatly improving the stability of the ambroxol hydrochloride solution. The preparation method provided by the present invention is simple and easy to operate, does not require a light-proof environment, has low production cost, and is easy to industrialize. When the ambroxol hydrochloride solution provided by the present invention is used alone or applied to an inhalation preparation, no preservative component needs to be added, the quality is reliable, the safety is good, and it is more suitable for clinical use requirements.

The invention discloses an oral suction tube preparation and filling and assembling equipment and a production method thereof.The oral suction tube preparation comprises a tubular container, and the first end and the second end of the tubular container are provided with a first blocking part and a second blocking part respectively; a first filter and a second filter are arranged in the tubular container between the first blocking part and the second blocking part, and an area for placing granular medicine is formed in the tubular container between the first filter and the second filter. Compared with the prior art, the first blocking part and the second blocking part are formed through the pipe opening of the tubular container, the blocking effect of the structure on the filter is good, the possibility that the filter falls off due to scraping is avoided, the filter cannot fall off due to the influence of the production technology, and the quality of oral suction pipe preparations is guaranteed. And secondly, additional accessories for arranging the first blocking part and the second blocking part are not needed, so that the cost is saved.

The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg / ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

1. Name of the designed product: environmental simulation box. 2. Use of the designed product: integrated control equipment for environmental parameters (temperature, humidity, static electricity) in the process of testing inhalation preparations. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The invention belongs to the field of biological medicine, and particularly relates to a sodium pyruvate aerosol inhalation preparation and a preparation method thereof. The aerosol inhalation preparation is prepared from the following raw materials in parts by weight: 0.04 to 0.09 part of baicalin-berbamine / sodium pyruvate clathrate compound freeze-dried powder and 100 parts of normal saline, the preparation process of the baicalin-berbamine comprises the following steps: reacting berbamine with 4-chlorphenyl glycidyl ether to obtain an intermediate A, mixing the intermediate A with a baicalin solution, reacting in the presence of a catalyst, and purifying after the reaction is completed to obtain the baicalin-berbamine. The sodium pyruvate aerosol inhalation preparation can effectively relieve asthma symptoms, and has excellent antibacterial activity, stability and biological activity.

The invention belongs to the field of biological medicine, and particularly relates to a sodium pyruvate aerosol inhalation preparation and a preparation method and application thereof. The aerosol inhalation preparation comprises the following components: sodium pyruvate, modified glycyrrhizic acid, a pH regulator and water for injection, the concentration of the sodium pyruvate is 50-120 mg / mL, the concentration of the modified glycyrrhizic acid is 5-40 mg / mL, and the pH value of the preparation is 6.5-7. By adding the modified glycyrrhizic acid, the stability and bioavailability of the sodium pyruvate can be effectively improved. In addition, sodium pyruvate and modified glycyrrhizic acid in the aerosol inhalation preparation take effect synergistically, and the pulmonary fibrosis process of patients with chronic obstructive pulmonary diseases can be effectively delayed.

The application relates to the technical field of pharmaceutical preparation mixing processes, in particular to a stirring device and a high-speed centrifugal device adopting the stirring device, which comprises a stirring paddle and a directional rotor, the stirring paddle and the directional rotor are coaxially and oppositely arranged, and are used for providing opposite shearing forces when rotating. Compared with the prior art, the application has the advantages that when two or more materials with large particle size difference and large proportion difference are mixed, the materials can reach a uniform and stable state in a short time under the action of high shearing force, the RSD value of content detection of random sampling in the tank is at a low level, and the mixed materials can meet the tanking requirements of powder for inhalation preparations.

The invention belongs to the technical field of veterinary traditional Chinese medicine preparations, and particularly relates to a veterinary traditional Chinese medicine compound aerosol inhalation preparation which is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process. The raw material medicines comprise, by weight, 15-30 parts of honeysuckle, 12-25 parts of fructus forsythiae, 10-20 parts of radix isatidis, 8-18 parts of platycodon grandiflorum, 6-15 parts of mint, 5-12 parts of liquorice, 6-14 parts of almond, 8-16 parts of folium mori, 10-22 parts of chrysanthemum and 8-18 parts of scutellaria baicalensis; the requirements of the raw material medicines are as follows: the honeysuckle is a dry flower bud or a flower with initial blooming of a honeysuckle plant, and is dried at low temperature, and the water content is 8-12%; the traditional Chinese medicine composition is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process, has the advantages of high targeting property, quick response, definite curative effect, small toxic and side effects, difficulty in drug resistance generation and the like, is excellent in atomization performance, is suitable for group administration, and can effectively solve the problem of prevention and treatment of respiratory diseases of livestock and poultry.

The invention belongs to the field of medicine product manufacturing, relates to manufacturing and quality control of inhalation preparation medicine products, and provides a drug delivery particle collecting device used in inhalation preparation in-vitro research and evaluation. By optimizing the structure of the device, the provided drug delivery particle collecting device is not only suitable for collecting and measuring the traditional delivery dosage, but also especially suitable for applying the delivered drug particles to in-vitro dissolution evaluation; the medicine particles collected by the device provided by the invention can still keep extremely high dissolution curve similarity under different medicine deposition amounts (the similarity factor f2 of the optimal device can reach 90.6). On the basis, the influence of the medicine deposition amount on the dissolution rate can be avoided, and the product quality of the inhaled preparation medicine can be evaluated more objectively, so that the product research and development and quality control of the inhaled preparation new medicine or the imitated medicine can be smoothly promoted.

The invention discloses a compound polymyxin inhalation preparation which is composed of polymyxin polypeptides, aminoglycoside antibiotics and pharmaceutically acceptable auxiliary materials, the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the inhalation preparation is (1: 20)-(1: 80), and the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the compound proportion is 1t compared with the molar ratio of a single component or the molar ratio of the aminoglycoside antibiotics in the single component; a compound proportion condition of 1: 20 can significantly reduce lung toxicity and also can achieve a drug effect of significantly eliminating lung infection multi-drug-resistant bacteria, the compound drug is delivered by adopting an inhalation liquid preparation form, the total drug delivery efficiency of aerosol inhalation is greatly improved, the median particle size of the drug is smaller, the proportion of particles smaller than 5 [mu] m exceeds 55%, and the drug delivery efficiency of aerosol inhalation is greatly improved. The medicine is more easily inhaled into the lung to achieve an anti-infection treatment effect.

The invention relates to the field of pharmaceutical preparations, in particular to an ambroxol hydrochloride solution and a preparation method and application thereof. According to the invention, the diethylenetriaminepentaacetic acid is used as a stabilizer component of the ambroxol hydrochloride solution in a small amount, and the diethylenetriaminepentaacetic acid has strong coordination ability and can interact with other molecules in the solution, so that the stability of the ambroxol hydrochloride solution is greatly improved. The preparation method provided by the invention is simple and easy to operate, does not need a dark environment, is low in production cost and is easy for industrial production. The ambroxol hydrochloride solution provided by the invention does not need to be added with preservative components or when the ambroxol hydrochloride solution is applied to an inhalation preparation, is reliable in quality and good in safety, and is more suitable for clinical use requirements.

The invention relates to preparations for inhalation and to methods for preventing or treating equine asthma in horses, wherein the preparation contains a vasoactive intestinal peptide (VIP) receptor agonist, in particular aviptadil.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non-pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

The invention discloses a preparation method of a cell membrane-based nucleic acid drug-loaded biological vesicle inhalation preparation. The preparation method comprises the following steps: preparing target cells into a cell suspension; repeatedly extruding the cell suspension through an extrusion device to obtain extrusion liquid; carrying out differential centrifugation on the extruded liquid, and collecting the biological vesicles; loading a nucleic acid drug into the biological vesicles; wherein the differential centrifugation comprises two centrifugation steps, and the centrifugation conditions are as follows: 1) the centrifugal force is 2,000-10,000 g, and the centrifugation time is 10-60 minutes; and (2) the centrifugal force is 16,000 to 100,000 g, and the centrifugal time is 10 to 120 minutes. The invention also discloses application of the cell membrane-based nucleic acid drug-loaded biological vesicle inhalation preparation obtained by the preparation method in preparation of drugs for treating lung diseases. The nucleic acid drug-loaded biological vesicle inhalation preparation prepared by the invention can be used for efficiently loading a nucleic acid drug and efficiently delivering the nucleic acid drug to the lung through atomization administration, and the basic character characterization and the drug-loading capability of the atomized preparation are basically consistent with those of the preparation before atomization.

The present invention relates to a dry powder composition for an inhalation formulation comprising formoterol or a pharmaceutically acceptable salt thereof, a tiotropium bromide anhydride and a pharmaceutically acceptable carrier. The synthesis methods of the formoterol and the tiotropium bromide are respectively realized through specific chemical reaction steps, and finally high-purity active ingredients are obtained. The weight ratio of the active ingredients to the carrier in the composition is 1: (1-15): (50-50000), and the carrier can be selected from lactose, cane sugar, mannitol or amino acid and the like. The preparation method comprises the following steps: micronizing, mixing, filling into hollow capsules, and finally preparing a finished product through aluminum-plastic packaging. The composition disclosed by the invention has good chemical stability and high inhalation efficiency, can be kept for more than two years at normal temperature, and is accurately and uniformly administered in a targeted lung through a dry powder inhalation device, so that formoterol and tiotropium bromide synergistically play a role in relaxing bronchial smooth muscles, and clinical requirements are met.

The invention belongs to the technical field of inhalation preparations and pulmonary drug delivery, and particularly relates to an atomization preparation for vitamin K inhalation drug delivery and preparation and application thereof. According to the preparation, dipalmitoyl phosphatidylcholine, cholesterol and optional anionic phospholipid are adopted to construct a bionic lung surface activity liposome skeleton LA1, an MK-7 organic phase is intercalated into a liposome double-layer hydrophobic area under the condition of controlling temperature and an energy path, and a continuous phase containing sodium chloride, propylene glycol and a pH regulator is matched to form an isotonic near-neutral environment; a neutral oil phase, a fat-soluble antioxidant, an optional metal chelating agent and a viscosity modifier can be introduced to synergistically optimize the atomization performance. The apparent viscosity of the prepared atomization preparation at 25 DEG C is 1.0-2.5 mPa.s, the osmotic pressure is 280-320 mOsm / kg, the average particle size of lipidosome Z is 80-150 nm, the PDI is not larger than 0.25, the mass median diameter of fog drops atomized by a vibration net type atomizer is 2.0-3.0 microns, the fine particle fraction is not smaller than 60%, and the MK-7 content retention rate is not lower than 90% after 6 months of accelerated storage at 25-40 DEG C.

Provided herein are formulations designed for administration by inhalation, including aqueous based compositions and dry powder compositions. The compositions described herein comprise a nitric oxide (NO) releasing compound, along with one or more additional agents, additives, and / or carriers. The compositions described herein exhibit a heat of decomposition of no greater than 300 J / g. Also described herein are methods of treating respiratory diseases in a subject, comprising administering to the subject an effective amount of a composition described herein.

The present invention relates to the use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, belonging to the field of pharmaceutical technology. The use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, the chemical structural formula of the fingolimod is as follows. The present invention adopts the administration method of oral and nasal inhalation, uses fingolimod to treat ischemic stroke, enhances the aggregation of the drug in the lungs, inhibits the migration of pulmonary immune cells to the brain, thereby reducing the inflammation at the stroke site in the brain parenchyma, improving the damage to the nervous system at the stroke site, and promoting the recovery of damaged nerve function. Moreover, the oral and nasal inhalation administration method avoids the side effects such as cardiac conduction block and bradycardia that may be caused when fingolimod is taken orally, and provides a new type of safe and effective administration route for patients with cerebral infarction, especially those with heart disease.

The invention relates to the technical field of inhalation preparations, in particular to an inhalation preparation for relieving or treating upper respiratory tract infection and a preparation method and application thereof. The inhalation preparation comprises an active pharmaceutical ingredient, and the active pharmaceutical ingredient is andrographolide; the inhalation preparation also comprises pharmaceutically acceptable auxiliary materials; the pharmaceutically acceptable auxiliary materials comprise one or more of a solvent, a cosolvent, a propellant, a carrier / diluent, a pH regulator, an antistatic agent and a stabilizer. The prescriptions and the preparation methods of the aerosol, the dry powder inhalation and the spray are suitable for industrial production, and clinical tests prove that the prepared inhalation preparation has a remarkable relieving or treating effect on upper respiratory tract infection.

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.